702 related articles for article (PubMed ID: 34024407)
21. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases.
Fischer A; Distler J
Clin Rheumatol; 2019 Oct; 38(10):2673-2681. PubMed ID: 31423560
[TBL] [Abstract][Full Text] [Related]
22. Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD.
Shumar JN; Chandel A; King CS
J Clin Med; 2021 May; 10(11):. PubMed ID: 34070297
[TBL] [Abstract][Full Text] [Related]
23. Advances with pharmacotherapy for the treatment of interstitial lung disease.
Comes A; Sgalla G; Perrotta A; Richeldi L
Expert Opin Pharmacother; 2022 Mar; 23(4):483-495. PubMed ID: 34907821
[TBL] [Abstract][Full Text] [Related]
24. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.
Hambly N; Farooqi MM; Dvorkin-Gheva A; Donohoe K; Garlick K; Scallan C; Chong SG; MacIsaac S; Assayag D; Johannson KA; Fell CD; Marcoux V; Manganas H; Morisset J; Comes A; Fisher JH; Shapera S; Gershon AS; To T; Wong AW; Sadatsafavi M; Wilcox PG; Halayko AJ; Khalil N; Cox G; Richeldi L; Ryerson CJ; Kolb M
Eur Respir J; 2022 Oct; 60(4):. PubMed ID: 35273032
[TBL] [Abstract][Full Text] [Related]
25. Recent Advances and Future Needs in Interstitial Lung Diseases.
Jones MG; Richeldi L
Semin Respir Crit Care Med; 2016 Jun; 37(3):477-84. PubMed ID: 27231869
[TBL] [Abstract][Full Text] [Related]
26. Clinical Overview of Progressive Fibrotic Interstitial Lung Disease.
Case AH
Front Med (Lausanne); 2022; 9():858339. PubMed ID: 35372405
[TBL] [Abstract][Full Text] [Related]
27. Acute exacerbations of fibrotic interstitial lung diseases.
Suzuki A; Kondoh Y; Brown KK; Johkoh T; Kataoka K; Fukuoka J; Kimura T; Matsuda T; Yokoyama T; Fukihara J; Ando M; Tanaka T; Hashimoto N; Sakamoto K; Hasegawa Y
Respirology; 2020 May; 25(5):525-534. PubMed ID: 31426125
[TBL] [Abstract][Full Text] [Related]
28. Progressive fibrotic interstitial lung disease.
Pereira CAC; Cordero S; Resende AC
J Bras Pneumol; 2023; 49(5):e20230098. PubMed ID: 37610955
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.
Richeldi L; Varone F; Bergna M; de Andrade J; Falk J; Hallowell R; Jouneau S; Kondoh Y; Morrow L; Randerath W; Strek M; Tabaj G
Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578333
[TBL] [Abstract][Full Text] [Related]
30. A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease.
Wong AW; Lee TY; Johannson KA; Assayag D; Morisset J; Fell CD; Fisher JH; Shapera S; Gershon AS; Cox G; Halayko AJ; Hambly N; Manganas H; Sadatsafavi M; Wilcox PG; To T; Marcoux V; Khalil N; Kolb M; Ryerson CJ
Respir Res; 2020 Dec; 21(1):322. PubMed ID: 33287805
[TBL] [Abstract][Full Text] [Related]
31. Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis.
Piotrowski WJ; Martusewicz-Boros MM; Białas AJ; Barczyk A; Batko B; Błasińska K; Boros PW; Górska K; Grzanka P; Jassem E; Jastrzębski D; Kaczyńska J; Kowal-Bielecka O; Kucharz E; Kuś J; Kuźnar-Kamińska B; Kwiatkowska B; Langfort R; Lewandowska K; Mackiewicz B; Majewski S; Makowska J; Miłkowska-Dymanowska J; Puścińska E; Siemińska A; Sobiecka M; Soroka-Dąda RA; Szołkowska M; Wiatr E; Ziora D; Śliwiński P
Adv Respir Med; 2022 Oct; 90(5):425-450. PubMed ID: 36285980
[TBL] [Abstract][Full Text] [Related]
32. The Role of Lung Microbiome in Fibrotic Interstitial Lung Disease-A Systematic Review.
Puiu R; Motoc NS; Lucaciu S; Ruta MV; Rajnoveanu RM; Todea DA; Man MA
Biomolecules; 2024 Feb; 14(3):. PubMed ID: 38540667
[TBL] [Abstract][Full Text] [Related]
33. The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease.
Sarkar P; Avram C; Chaudhuri N
Expert Rev Respir Med; 2020 Oct; 14(10):1001-1008. PubMed ID: 32567402
[TBL] [Abstract][Full Text] [Related]
34. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
[No Abstract] [Full Text] [Related]
35. Body weight loss is a simple and useful indicator of prognosis and predictive tolerability in the first year of nintedanib therapy in patients with interstitial lung disease.
Yamakawa H; Sato S; Ohta H; Kusano K; Kawabe R; Oba T; Uzuka C; Sasaki H; Akasaka K; Amano M; Takemura T; Araya J; Matsushima H
Respir Investig; 2024 Jul; 62(4):551-557. PubMed ID: 38663299
[TBL] [Abstract][Full Text] [Related]
36. Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers.
Faverio P; Piluso M; De Giacomi F; Della Zoppa M; Cassandro R; Harari S; Luppi F; Pesci A
Respiration; 2020; 99(10):838-845. PubMed ID: 33264777
[TBL] [Abstract][Full Text] [Related]
37. Real-life prevalence of progressive fibrosing interstitial lung diseases.
Gagliardi M; Berg DV; Heylen CE; Koenig S; Hoton D; Tamirou F; Pieters T; Ghaye B; Froidure A
Sci Rep; 2021 Dec; 11(1):23988. PubMed ID: 34907290
[TBL] [Abstract][Full Text] [Related]
38. Association between Pepsin in Bronchoalveolar Lavage Fluid and Prognosis of Chronic Fibrosing Interstitial Lung Disease.
Kim Y; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
Tohoku J Exp Med; 2018 Nov; 246(3):147-153. PubMed ID: 30405002
[TBL] [Abstract][Full Text] [Related]
39. Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs).
Joannes A; Voisin T; Morzadec C; Letellier A; Gutierrez FL; Chiforeanu DC; Le Naoures C; Guillot S; De Latour BR; Rouze S; Jaillet M; Crestani B; Wollin L; Jouneau S; Vernhet L
Pulm Pharmacol Ther; 2023 Dec; 83():102267. PubMed ID: 37972706
[TBL] [Abstract][Full Text] [Related]
40. Acute exacerbations of progressive-fibrosing interstitial lung diseases.
Kolb M; Bondue B; Pesci A; Miyazaki Y; Song JW; Bhatt NY; Huggins JT; Oldham JM; Padilla ML; Roman J; Shapera S
Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]